

BILL SUMMARY
2nd Session of the 60th Legislature

Bill No.:	HB4457
Version:	INT
Request Number:	14549
Author:	Newton
Date:	2/12/2026
Impact:	Please see previous summary of this measure

Research Analysis

HB 4457, as introduced, provides that a pharmacy benefits manager cannot acquire direct or indirect interest in a license for the retail sale of drugs or medicine in the state. The State Board of Pharmacy will either revoke or not renew a license of any entity violating this, upon the effective date. Until Sept. 1, 2028, the Board may issue a limited use license for certain rare, orphan, or limited distribution drugs that would otherwise be unavailable on the market. The Board of Pharmacy will also make rules to implement the measure and they may extend the use of a license or issue a renewal of a license for a pharmacy that offers critical patient health care services for a period of time if there is a pending sale to an eligible buyers. This measure will not apply to pharmacies in certain circumstances. The State Board of Pharmacy must conduct an initial assessment of each active pharmacy license and notify any licensed holder that the Board reasonably believe will violate these provisions. A pharmacy licensed holder with written notice to patients and their prescribing health care provider that they can no longer dispense retail drugs.

Prepared By: Suzie Nahach, House Research Staff

Fiscal Analysis

The measure is currently under review and impact information will be completed.

Prepared By: House Fiscal Staff

Other Considerations

None.